Related Experiment Video
Updated: Jan 29, 2026

Author Spotlight: Decoding Metastasis-to-Metastasis Seeding Using a New In Vivo Technique for Tracking Breast Cancer Spread
Published on: July 7, 2023
PLOD3 suppression exerts an anti-tumor effect on human lung cancer cells by modulating the PKC-delta signaling
Jeong-Hwa Baek1,2, Hong Shik Yun1, Gyoo Taik Kwon1
1Division of Radiation Biomedical Research, Korea Institute of Radiological & Medical Sciences, Seoul, 01812, Korea.
Abstract:
Current lung cancer treatments are far from satisfactory; thus, finding novel treatment targets is crucial. We recently identified procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3 (PLOD3), which is involved in fibrosis and tissue remodeling as a radioresistance-related protein in lung cancer cells; however, its mechanism is unclear. In this study, we designed human PLOD3-specific short interfering (si)RNAs and tested their effects on tumor growth inhibition in vitro and in vivo. PLOD3 knockdown overcame chemoresistance and decreased radioresistance by inducing caspase-3-dependent apoptosis in lung cancer cells. Furthermore, PLOD3 interacted with PKCδ to activate caspase-2,4-dependent apoptosis through ER-stress-induced IRE1α activation and the downstream unfolded-protein response pathway. In a mouse xenograft model, PLOD3 knockdown promoted radiation-induced tumor growth inhibition, without side effects. Moreover, lung cancer patients with high PLOD3 expression showed poorer prognosis than those with low PLOD3 expression upon radiotherapy, suggesting that PLOD3 promotes tumor growth. Therefore, PLOD3 siRNA suppresses radioresistance and chemoresistance by inducing apoptosis and renders PLOD3 as a candidate lung cancer biomarker. PLOD3 gene therapy might enhance the efficacy of radiotherapy or chemotherapy in lung cancer patients.
Insights
Targeting procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3 (PLOD3) with siRNA inhibits lung cancer growth. PLOD3 knockdown overcomes chemoresistance and radioresistance by inducing apoptosis, suggesting PLOD3 as a therapeutic target and biomarker.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Lung cancer treatments require novel targets due to unsatisfactory outcomes.
- Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3 (PLOD3) is implicated in fibrosis and tissue remodeling.
- PLOD3 is identified as a radioresistance-related protein in lung cancer cells, but its mechanism remains unclear.
Purpose of the Study:
- To investigate the role of PLOD3 in lung cancer radioresistance and chemoresistance.
- To evaluate the therapeutic potential of targeting PLOD3 using short interfering (si)RNAs.
- To elucidate the molecular mechanisms by which PLOD3 influences cancer cell apoptosis and treatment response.
Main Methods:
- Design and application of human PLOD3-specific siRNAs.
- In vitro and in vivo experiments to assess tumor growth inhibition.
- Analysis of apoptosis pathways, including caspase activation and the unfolded-protein response (UPR).
- Correlation analysis between PLOD3 expression and patient prognosis.
Main Results:
- PLOD3 knockdown sensitized lung cancer cells to chemotherapy and radiotherapy by inducing caspase-3-dependent apoptosis.
- PLOD3 interacts with PKCδ, activating caspase-2,4-dependent apoptosis via ER-stress-induced IRE1α activation and UPR.
- PLOD3 siRNA significantly enhanced radiation-induced tumor growth inhibition in a mouse xenograft model without observable side effects.
- High PLOD3 expression in lung cancer patients correlated with poorer prognosis following radiotherapy.
Conclusions:
- PLOD3 plays a critical role in promoting lung cancer radioresistance and chemoresistance.
- PLOD3 siRNA effectively suppresses tumor growth by inducing apoptosis, presenting a potential therapeutic strategy.
- PLOD3 serves as a promising biomarker for predicting treatment response and patient prognosis in lung cancer.
- Targeting PLOD3 offers a potential approach to enhance the efficacy of radiotherapy and chemotherapy in lung cancer patients.
Related Concept Videos
Notch Signaling Pathway
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not...
Hedgehog Signaling Pathway
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
The Delta-to-Delta Circuit
Non-Canonical Wnt Signaling Pathways
Canonical Wnt Signaling Pathway

